Abiomed Pumps Up Temporary Heart Assist Offerings With AB5000 Ventricle
This article was originally published in The Gray Sheet
Executive Summary
Abiomed expects FDA's Sept. 25 approval of a PMA supplement for its AB5000 Ventricle biventricular cardiac assist system to help reinvigorate stagnant temporary cardiac assist capital equipment sales
You may also be interested in...
Abiomed Taps GE Exec Minogue For CEO Slot, Adding Marketing Expertise
Newly appointed Abiomed President & CEO Michael Minogue's goals for 2004 include corporate profitability and a full rollout of the AB5000 Circulatory Support System
Abiomed Taps GE Exec Minogue For CEO Slot, Adding Marketing Expertise
Newly appointed Abiomed President & CEO Michael Minogue's goals for 2004 include corporate profitability and a full rollout of the AB5000 Circulatory Support System
Spinal Implant Sales Make, Break Orthopedic Stocks In September
Biomet's ability to beat Wall Street's first-quarter revenue estimates by roughly $9 mil. due to strong spinal implant sales drove up the company's stock 12.6% in September